China turns first major country to let preschoolers have emergency vaccine

The move comes amid reports that young people with the disease could be as infectious as adults

Chinese Preschoolers
It’s not yet confirmed when this age group will receive their first doses of the vaccine in China. Phase I and Phase II research
Bloomberg News
2 min read Last Updated : Jun 05 2021 | 10:56 AM IST
China authorized the emergency use of Sinovac Biotech Ltd.’s coronavirus vaccine for children, becoming the first major country to grant approval for those as young as three.

The move comes amid reports that young people with the disease could be as infectious as adults. Singapore, Hong Kong and some U.S. states have so far authorized the use of Covid-19 vaccines against children 12 years and above.

It’s not yet confirmed when this age group will receive their first doses of the vaccine in China. Phase I and Phase II research, involving several hundred participants, showed that the Sinovac vaccine is as safe and effective for children as it is for adults, the company’s Chief Executive Officer Yin Weidong told state broadcaster China Central Television on Friday.

Read More: Pfizer Covid-19 vaccine now expanded to US children as young as 12

“The same vaccine, the same amount, and the same process can be used for children aged between 3 and 17,” Yin said. ”China’s health authority will push forward vaccine use for different age groups in an orderly manner based on China’s epidemic needs and population structure.”

The World Health Organization approved Sinovac’s vaccine as part of its emergency use listing on Tuesday for people aged 18 and older. The authorization granted to the Sinovac shot is the second given to a Chinese Covid vaccine, after state-owned Sinopharm Group Co. secured WHO’s nod for emergency use in early May.

Also cleared for emergency use by the WHO are vaccines from Pfizer Inc. and partner BioNTech SE, AstraZeneca Plc, Johnson & Johnson and Moderna Inc.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusCoronavirus VaccineChina

Next Story